Please use this identifier to cite or link to this item:
Title: Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation
Authors: Chioh, Florence Wen Jing
Fong, Siew-Wai
Young, Barnaby Edward
Wu, Kan Xing
Siau, Anthony
Krishnan, Shuba
Chan, Yi-Hao
Carissimo, Guillaume
Teo, Louis L. Y.
Gao, Fei
Tan, Ru San
Zhong, Liang
Koh, Angela S.
Tan, Seow-Yen
Tambyah, Paul A.
Renia, Laurent
Ng, Lisa F. P.
Lye, David C.
Cheung, Christine
Keywords: Science::Medicine
Issue Date: 2021
Source: Chioh, F. W. J., Fong, S., Young, B. E., Wu, K. X., Siau, A., Krishnan, S., Chan, Y., Carissimo, G., Teo, L. L. Y., Gao, F., Tan, R. S., Zhong, L., Koh, A. S., Tan, S., Tambyah, P. A., Renia, L., Ng, L. F. P., Lye, D. C. & Cheung, C. (2021). Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. ELife, 10, e64909-.
Project: COVID19RF-001
Journal: eLife
Abstract: Numerous reports of vascular events after an initial recovery from COVID-19 form our impetus to investigate the impact of COVID-19 on vascular health of recovered patients. We found elevated levels of circulating endothelial cells (CECs), a biomarker of vascular injury, in COVID-19 convalescents compared to healthy controls. In particular, those with pre-existing conditions (e.g., hypertension, diabetes) had more pronounced endothelial activation hallmarks than non-COVID-19 patients with matched cardiovascular risk. Several proinflammatory and activated T lymphocyte-associated cytokines sustained from acute infection to recovery phase, which correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Notably, we found higher frequency of effector T cells in our COVID-19 convalescents compared to healthy controls. The activation markers detected on CECs mapped to counter receptors found primarily on cytotoxic CD8+ T cells, raising the possibility of cytotoxic effector cells targeting activated endothelial cells. Clinical trials in preventive therapy for post-COVID-19 vascular complications may be needed.
ISSN: 2050-084X
DOI: 10.7554/eLife.64909
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Organisations: A*STAR Infectious Diseases Labs
Singapore Immunology Network, A*STAR
Institute of Molecular and Cell Biology, A*STAR
Rights: © 2021, Chioh et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
elife-64909-v1.pdf3.22 MBAdobe PDFThumbnail

Citations 5

Updated on Feb 15, 2024

Web of ScienceTM
Citations 5

Updated on Oct 25, 2023

Page view(s)

Updated on Feb 20, 2024

Download(s) 50

Updated on Feb 20, 2024

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.